GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiromic BioPharma Inc (OTCPK:KRBP) » Definitions » Effective Interest Rate on Debt %

Kiromic BioPharma (Kiromic BioPharma) Effective Interest Rate on Debt % : 29.42% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kiromic BioPharma Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Kiromic BioPharma's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $4.28 Mil. Kiromic BioPharma's average total debt for the quarter that ended in Mar. 2024 was $14.56 Mil. Therefore, Kiromic BioPharma's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 29.42%.


Kiromic BioPharma Effective Interest Rate on Debt % Historical Data

The historical data trend for Kiromic BioPharma's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiromic BioPharma Effective Interest Rate on Debt % Chart

Kiromic BioPharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial - 0.64 2.60 3.39 14.84

Kiromic BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.61 12.14 16.18 18.83 29.42

Competitive Comparison of Kiromic BioPharma's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Kiromic BioPharma's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiromic BioPharma's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiromic BioPharma's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Kiromic BioPharma's Effective Interest Rate on Debt % falls into.



Kiromic BioPharma Effective Interest Rate on Debt % Calculation

Kiromic BioPharma's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -1.852/( (9.411+15.543)/ 2 )
=-1  *  -1.852/12.477
=14.84 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=4.459 + 4.952
=9.411

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.912 + 14.631
=15.543

Kiromic BioPharma's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2023 )+Total Debt  (Q: Mar. 2024 ))/ count )
=-1  *  -4.284/( (15.543+13.581)/ 2 )
=-1  *  -4.284/14.562
=29.42 %

where

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.912 + 14.631
=15.543

Total Debt  (Q: Mar. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.747 + 12.834
=13.581

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Kiromic BioPharma  (OTCPK:KRBP) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Kiromic BioPharma Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Kiromic BioPharma's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiromic BioPharma (Kiromic BioPharma) Business Description

Industry
Traded in Other Exchanges
N/A
Address
7707 Fannin Street, Suite 140, Houston, TX, USA, 77054
Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.
Executives
Brian Hungerford officer: CFO 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Pamela Misajon director 7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Michael Catlin director 7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Karen Reeves director 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Francis X Tirelli director 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Daniel Grant Clark officer: Interim CFO 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Internati Maurizio Chiriva director, officer: Chairman, CEO, and President 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Michael Charles Ryan officer: Chief Technology Officer 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Ignacio Nunez officer: See Remarks 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Jerry A. Schneider director ONE VISION DRIVE, NATICK MA 01760
Michael Nagel director C/O VASCULAR SOLUTIONS INC, 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Pietro Bersani director C/O FUEL SYSTEMS SOLUTIONS, INC., 780 THIRD AVE. 25TH FLOOR, NEW YORK NY 10017
Scott Dahlbeck officer: Chief Medical Officer 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Americo Cicchetti director 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Gianluca Rotino director, officer: CSIO 7707 FANNIN, SUITE 140, HOUSTON TX 77054

Kiromic BioPharma (Kiromic BioPharma) Headlines

From GuruFocus